Image

A Phase 3 Study to Evaluate the Efficacy and Safety of Pegcetacoplan in Adults at High Risk of Delayed Graft Function (DGF) Following Kidney Allograft Transplantation

A Phase 3 Study to Evaluate the Efficacy and Safety of Pegcetacoplan in Adults at High Risk of Delayed Graft Function (DGF) Following Kidney Allograft Transplantation

Recruiting
18 years and older
All
Phase 3

Powered by AI

Overview

A Phase 3 Study to Evaluate the Efficacy and Safety of Pegcetacoplan in Adults at High Risk of Delayed Graft Function (DGF) Following Kidney Allograft Transplantation

Eligibility

Inclusion Criteria:

  1. Aged at least 18 years
  2. Have end-stage kidney disease and be on the waiting list for a kidney transplant from a deceased donor.
  3. Be on dialysis at the time of your transplant and produce very little urine (less than 200 mL per day equivalent to ≤1 cup). You must have been on dialysis for at least 3 months.
  4. Be receiving your first or second kidney transplant from a deceased donor. If this is your second transplant:
    1. It cannot be due to a serious infection or a serious blood clot in your previous transplant.
    2. Your calculated Panel Reactive Antibody (CPRA) level must be below 50%.
  5. Be getting a donor kidney that meets the study's specific requirements.
  6. Be at low to medium risk of transplant rejection, and be scheduled to receive:
    1. A medication called ATG as part of your transplant procedure.
    2. Steroids (corticosteroids) as part of your treatment at the time of screening.
    3. A medication called tacrolimus (or a similar drug) after your transplant, according to usual medical practice.
  7. Have received certain vaccines before starting the study treatment, specifically:
    1. Pneumococcal (S. pneumoniae)
    2. Meningococcal (N. meningitidis types A, C, W, Y, and B)
    3. Haemophilus influenzae type B

If you haven't had these vaccines, you may still qualify to be part of the study, provided your doctor plans to administer preventive antibiotics until vaccination can be given per protocol, and with notification to the sponsor.

Exclusion Criteria:

  1. Have taken part in another medical research study or used an experimental drug, treatment, or device in the past 30 days (or longer, depending on the drug).
  2. Have recently used certain medications that affect the immune system, such as rituximab, belimumab, or other approved complement-blocking drugs.
  3. Weigh less than 20kg or more than 120kg at screening.
  4. Have or had recently had any of the following infections:
    1. Hepatitis B or Hepatitis C (unless treated and no longer active).
    2. HIV (human immunodeficiency virus) at any time.
  5. Have had cancer in the past 5 years, unless it was:
    1. A small, treated skin cancer (like basal or squamous cell), or
    2. A very small kidney cancer that was found early and treated.
  6. Have received any other organ transplant (except for one previous kidney transplant), or are scheduled for a transplant involving more than one organ.

Study details
    Delayed Graft Function
    End Stage Renal Disease
    Deceased Donor Kidney Transplant

NCT07020832

Apellis Pharmaceuticals, Inc.

13 May 2026

Step 1 Get in touch with the nearest study center
We have submitted the contact information you provided to the research team at {{SITE_NAME}}. A copy of the message has been sent to your email for your records.
Would you like to be notified about other trials? Sign up for Patient Notification Services.
Sign up

Send a message

Enter your contact details to connect with study team

Investigator Avatar

Primary Contact

  Other languages supported:

First name*
Last name*
Email*
Phone number*
Other language

FAQs

Learn more about clinical trials

What is a clinical trial?

A clinical trial is a study designed to test specific interventions or treatments' effectiveness and safety, paving the way for new, innovative healthcare solutions.

Why should I take part in a clinical trial?

Participating in a clinical trial provides early access to potentially effective treatments and directly contributes to the healthcare advancements that benefit us all.

How long does a clinical trial take place?

The duration of clinical trials varies. Some trials last weeks, some years, depending on the phase and intention of the trial.

Do I get compensated for taking part in clinical trials?

Compensation varies per trial. Some offer payment or reimbursement for time and travel, while others may not.

How safe are clinical trials?

Clinical trials follow strict ethical guidelines and protocols to safeguard participants' health. They are closely monitored and safety reviewed regularly.
Add a private note
  • abc Select a piece of text.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.